BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Broome CM, Cunningham JM, Mullins M, Jiang X, Bylsma LC, Fryzek JP, Rosenthal A. Increased risk of thrombotic events in cold agglutinin disease: A 10-year retrospective analysis. Res Pract Thromb Haemost 2020;4:628-35. [PMID: 32548562 DOI: 10.1002/rth2.12333] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Berentsen S, Barcellini W, D'Sa S, Jilma B. Sutimlimab for treatment of cold agglutinin disease: why, how and for whom? Immunotherapy 2022. [PMID: 35946351 DOI: 10.2217/imt-2022-0085] [Reference Citation Analysis]
2 Imoto H, Yoshioka S, Nakagawa D, Hasegawa K, Kuroda H, Hasuike T, Doi A, Kusumoto T, Ishikawa T. Cold agglutinin anti-I antibodies in two patients with COVID-19. J Clin Lab Anal 2022;:e24629. [PMID: 35917437 DOI: 10.1002/jcla.24629] [Reference Citation Analysis]
3 Fattizzo B, Barcellini W. Autoimmune hemolytic anemia: causes and consequences. Expert Rev Clin Immunol 2022;:1-15. [PMID: 35702053 DOI: 10.1080/1744666X.2022.2089115] [Reference Citation Analysis]
4 Beecher SM, Quigley A, Gurney M, Hussey AJ, McInerney NM. Microvascular free tissue transfer in the setting of cold agglutinin disease. Microsurgery 2022. [PMID: 35611636 DOI: 10.1002/micr.30923] [Reference Citation Analysis]
5 Xiao Z, Murakhovskaya I. Development of New Drugs for Autoimmune Hemolytic Anemia. Pharmaceutics 2022;14:1035. [DOI: 10.3390/pharmaceutics14051035] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Gertz MA. Updates on the Diagnosis and Management of Cold Autoimmune Hemolytic Anemia. Hematology/Oncology Clinics of North America 2022. [DOI: 10.1016/j.hoc.2021.11.001] [Reference Citation Analysis]
7 Patriquin CJ, Pavenski K. O, wind, if winter comes … will symptoms be far behind?: Exploring the seasonality (or lack thereof) and management of cold agglutinin disease. Transfusion 2021. [PMID: 34893982 DOI: 10.1111/trf.16765] [Reference Citation Analysis]
8 Röth A, Fryzek J, Jiang X, Reichert H, Patel P, Su J, Morales Arias J, Broome CM. Complement-mediated hemolysis persists year round in patients with cold agglutinin disease. Transfusion 2021. [PMID: 34813663 DOI: 10.1111/trf.16745] [Reference Citation Analysis]
9 Joly F, Schmitt LA, Watson PAM, Pain E, Testa D. The Burden of Cold Agglutinin Disease on Patients’ Daily Life: An Online Survey of 50 American Patients (Preprint). JMIR Formative Research. [DOI: 10.2196/34248] [Reference Citation Analysis]
10 Schär DT, Daskalakis M, Mansouri B, Rovo A, Zeerleder S. Thromboembolic complications in autoimmune hemolytic anemia: Retrospective study. Eur J Haematol 2022;108:45-51. [PMID: 34551149 DOI: 10.1111/ejh.13710] [Reference Citation Analysis]
11 Berentsen S. How I treat cold agglutinin disease. Blood 2021;137:1295-303. [PMID: 33512410 DOI: 10.1182/blood.2019003809] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
12 Delvasto-Nuñez L, Jongerius I, Zeerleder S. It takes two to thrombosis: Hemolysis and complement. Blood Rev 2021;:100834. [PMID: 33985796 DOI: 10.1016/j.blre.2021.100834] [Reference Citation Analysis]
13 Tyczynski JE, Potluri R, Kilpatrick R, Mazumder D, Ghosh A, Liede A. Incidence and Risk Factors of Pneumonitis in Patients with Non-Small Cell Lung Cancer: An Observational Analysis of Real-World Data. Oncol Ther 2021. [PMID: 33909273 DOI: 10.1007/s40487-021-00150-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Capecchi M, Ciavarella A, Artoni A, Abbattista M, Martinelli I. Thrombotic Complications in Patients with Immune-Mediated Hemolysis. J Clin Med 2021;10:1764. [PMID: 33919638 DOI: 10.3390/jcm10081764] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
15 Murakhovskaya I. Rituximab Use in Warm and Cold Autoimmune Hemolytic Anemia. J Clin Med 2020;9:E4034. [PMID: 33322221 DOI: 10.3390/jcm9124034] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 Maslov DV, Simenson V, Jain S, Badari A. COVID-19 and Cold Agglutinin Hemolytic Anemia. TH Open 2020;4:e175-7. [PMID: 32844144 DOI: 10.1055/s-0040-1715791] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
17 Kamesaki T, Nishimura J, Wada H, Yu E, Tsao E, Morales J, Kanakura Y. Demographic characteristics, thromboembolism risk, and treatment patterns for patients with cold agglutinin disease in Japan. Int J Hematol 2020;112:307-15. [DOI: 10.1007/s12185-020-02899-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Su J, Bylsma LC, Jiang X, Morales Arias J, Jain N, Nordyke RJ. Healthcare resource utilization among commercially insured patients with cold agglutinin disease in the United States. Journal of Medical Economics 2020;23:902-7. [DOI: 10.1080/13696998.2020.1764006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]